After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) — Equity Insider News Commentary — The last […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.